Abstract CD81 is an integral membrane protein belonging to the tetraspanin superfamily. It has two extracellular domains that interact with cell surface proteins and two intracellular tails that contribute to cellular processes. Although there are considerable data about how CD81 affects T-and B-cell function, not much is known about how it impacts macrophages. To address this, we established four cell lines from mouse bone marrow in the presence of macrophage colony-stimulating factor and transfection with SV40 large T antigen. Two were CD81 −/− (ASD1 and ASD2) and two were CD81 +/− (2ASD1.10 and 2BSD1.10). Cells were Mac-2-, PU.1-, and c-fms-positive and all the cell lines were phagocytic indicating that they were macrophage-like. In mixtures of the two cell types in tissue culture, CD81
Introduction
CD81 is a 26-kDa cell-surface protein that is widely expressed across kingdoms and contributes to a variety of biological responses. CD81 shares about 60% protein sequence identity among various species and it is unique among tetraspanins because it is not glycosylated . These molecules span the plasma membrane four times (tetraspanins) and most of the sequence variation is in the large extracellular loop. The small extracellular loop and the cytoplasmic and transmembrane domains are highly conserved (Fernandez-Sesma et al. 1998) .
CD81 is expressed in all cell types, excluding red blood cells and platelets. Although ubiquitous, CD81 molecules have cell-type specific functions. On B cells, CD81 functions as part of the B-cell co-receptor complex, which consists of CD21, CD19, and Leu13 (an interferon inducible antigen) (Fearon and Carter 1995) . CD21 (also known as CR2) is a receptor for complement component C3d. Upon engagement the co-receptor complex cross-links with the B-cell receptor, thereby reducing the threshold for B-cell activation . The absence of CD81 prevents the formation of this molecular complex (Shoham et al. 2003) . Maecker and Levy (1997) found that CD19 expression was also reduced in mice lacking CD81, but these mice developed normal B cells.
On T cells, CD81 associates with CD4 and CD8. The cell-cell adhesiveness of thymocytes is regulated by a signal derived from CD81 through activation of the integrin, LFA-1, also known as CD18/CD11a. The selection of T cells requires the MHC peptide recognized by CD4 and CD8 along with molecules such as CD18/CD11a to form the T-cell receptor/CD3 complex (Todd et al. 1996; Mittelbrunn et al. 2002) . Once assembled, this complex works with CD3 to provide co-stimulatory signaling.
The role of CD81 in macrophage function is less clearly defined. In the absence of both CD81 and CD9, macrophages form giant cells when stimulated with concanavalin A (Takeda et al. 2003) . Osteoclastogenesis was also higher compared to normal mice (Takeda et al. 2003) . Therefore, there are some suggestions that CD81 affects macrophage function. To test this hypothesis, we generated macrophage cell lines from CD81 knock-out mice and heterozygous littermates. In this report, we detail the creation of these cell lines and document that CD81 expression regulates their growth.
Materials and Methods
Mice. C.129-cd81 TM1 mice were a generous donation by S. Levy (Stanford University Medical Center, CA) (Maecker and Levy 1997) . These mice were maintained on the Balb/c background by brother-sister crosses of homozygous CD81-negative males and heterozygous CD81 females because of infertility/low fecundity of homozygous CD81 females (Rubinstein et al. 2006 ). All offspring were genotyped for CD81 alleles as described below. Mice were maintained and reared in the animal facility of the Division of Biology at Kansas State University with approval and monitoring by the Institutional Animal Care and Use Committee.
Reagents. Dulbecco's Modified Eagle's Medium (DMEM) (Atlanta Biologicals, Lawerenceville, GA) was supplemented with 1% Nu Serum (Collaborative Biomedical Products, Bedford, MA), 1% Fetal Bovine Serum (FBS) (Atlanta Biologicals), and 10% Opti-MEM reduced Serum Medium (Invitrogen, Carlsbad, CA) (DMEM 2 ). Biomedium was made from DMEM 2 with an additional 50 µg per ml gentamycin (Atlanta Biologicals), 1.5 ng per ml recombinant mouse macrophage colony-stimulating factor (M-CSF; R&D Systems, Minneapolis, MN), and 10% LM929 supernatant. Phosphate-buffered saline (PBS): 0.8% NaCl, 0.002% KH 2 PO 4 , 0.02% KCl, and 0.115% NaHPO 4 anhydrous; pH 7.35. ACK lysing buffer reagent: 0.15 M NH 4 Cl, 10 mM KHCO 3 , and 0.1 mM Na 2 EDTA were also used in this study.
The TNF-sensitive fibroblast cell line LM929 was obtained from the American Type Culture Collection (CCL1.2, Rockville, MD). It was maintained in DMEM 2 and was passaged two to three times weekly. The supernatant from this cell line contains M-CSF (Armstrong et al. 1995) and was used to induce and maintain bone marrow macrophages in culture. Derived macrophage cell lines (i.e., ASD1, ASD2, 2ASD1.10, and 2BSD1.10) were maintained at 37°C in 8% CO 2 in 60-or 100-mm dishes and passaged at confluency.
Cells were dispersed using standard passaging methods (Beharka et al. 1998) . Solutions were tested and confirmed to be free of endotoxin using the Limulus Ameobocyte Lysate Assay (Associated of Cape Cod, Inc., East Falmouth, MA).
Peritoneal exudate macrophages were induced by intraperitoneal injection of 1.5 ml of sterile, 2.9% thioglycollate (DIFCO, Detroit, MI). Four days after injection, mice were anesthetized by Halothane (Halocarbon, Riveredge, NJ) inhalation and were euthanized by cervical dislocation. Peritoneal exudate macrophages were collected from euthanized mice by washing the peritoneal cavity twice with 12 ml of ice cold PBS.
Genotyping. Mice were genotyped using tail DNA and confirmed for all experimental animals from liver DNA obtained from the animal at the time of sacrifice. To obtain DNA for genotyping, 3 mm of tail was removed and digested as per manufacturer's instructions (DirectPCR Tail, Viagen Biotech, Los Angeles, CA). The digested samples containing the DNA were stored at 4°C until analyzed by standard polymerase chain reaction (PCR) methodologies.
The primers used were specific for sequences in the sixth and seventh exons of CD81 (Table 1) (Maecker and Levy 1997) . Primers specific for neo were used to detect the presence of the neo gene (Table 1) . Primers specific for the 14S ribosomal protein gene (Rhoads and Roufa 1985) were used to assess the quality of the DNA sample for instances where neo-or CD81-specific PCR reactions were negative (Table 1) . The amplicons, loaded in tandem, were detected in ethidium bromide-(Ethidium Bromide Tablets, 10 mg, MidSci., St. Louis, MO) stained 1.5% agarose (Agarose, Low EEL, Fisher Scientific, Pittsburgh, PA) gels (Table 1) .
Differentiation of bone marrow macrophages. Bone marrow cells were isolated from long bones (femora, tibiae, and humerii) as previously described (Armstrong et al. 1993) . The undifferentiated cells were resuspended in Biomedium, counted and 3 to 5×10 6 cells were plated per 100-mm dish. Cells were incubated at 37°C in 8% CO 2 and passaged for up to seven times but after multiple attempts, spontaneous immortalization did not occur as described for the C2D macrophage cells (Beharka et al. 1998) . Therefore, bone marrow cells were then transformed with SV40 large T antigen to create immortalized cell lines.
Transfection of bone marrow macrophages and detection of SV40 large T antigen. Bone marrow macrophages were incubated for 1 wk at 37°C in 8% CO 2 in Biomedium. Transfection was performed on cells between 50% and 75% confluency with SV40 large T antigen (Janabi et al. 1995; Beharka et al. 1998) . Cells were carefully washed with 2 to 3 ml of saline and the monolayer was covered with 3 ml of serum-free DMEM. In a 1.5-ml centrifuge tube, 193 µl of serum-free medium was mixed with 3 µl of Fugene 6 Transfection Reagent (R. F. Hoffmann-La Roche Ltd, Basel, Switzerland). The mixture was vortexed and incubated at room temperature for 5 min before adding 5 µg of pSV3-SV40-T antigen plasmid DNA (0.5 µg per µl) and again vortexed. The mixture was incubated at room temperature for 20 min and the entire contents of the tube were added to the plated cells. The cells were incubated at 37°C in 8% CO 2 for 24 h before 2 ml of Biomedium were added. Three days after transfection, the cells were returned to a normal culturing regimen (splitting two to three times per week).
Cells were assessed for T antigen expression by reverse transcriptase (RT)-PCR using the Access RT-PCR Kit (Promega, Madison, WI).
Limiting dilution cloning of cell lines. Cells were dispersed with trypsin/EDTA, pelleted, and were resuspended in DMEM 2 . The cells were counted and each dilution was plated in 48 wells of a Costar 96-well, flat-bottom tissue culture plate. A 1:10 serial dilution was generated starting at 1,000 cells/well in 100 µl DMEM 2 and ending at 0.01 cell/well. Cells were then incubated at 37°C in 8% CO 2 . Only clones that grew from dilutions having less than a 30% positive rate were selected and expanded.
Phagocytosis assays. Peritoneal exudate macrophages were recovered, washed in medium, counted, and plated at 1× 10 6 cells per well of 24-well tissue culture plates (Corning Costar, 3524, Cambridge, MA) . The peritoneal macrophages were incubated for 2 h at 37°C in 8% CO 2 . For the cell line macrophages, cells were plated at 5×10 5 cells per well and incubated at 37°C in 8% CO 2 overnight so that there would be 1×10 6 cells for the assay. Negative controls were incubated at 4°C while experimental samples were kept at 37°C for 2 h. Cytochalasin D from Zygosporium mansonii (Sigma Aldrich, St. Louis, MO) was then added to the cold negative control plate to additionally inhibit phagocytosis. Twenty-five microliters of red fluorescent polystyrene beads (diameter, 0.86 µm; Duke Scientific Corporation, Fremont, CA) were added to each well. Phagocytosis was stopped after 20 min by centrifuging the 24-well plates at 350×g for 5 min, removing the supernatant, and dispersing the cells with 500 µl of trypsin/ EDTA. The trypsin action was stopped by adding double the volume of PBS and transferring the suspended cells to 12×75-mm polystyrene tubes (Falcon, Brookings, SD). Cells were centrifuged for 5 min at 350×g and the supernatant was removed from the pellet. The cells were washed two additional times with 2 ml of PBS to remove free beads and suspended in 200 µl of 2% formalin/PBS. The cells were placed on ice and phagocytosis was assessed by flow cytometry using a FACS Caliber analytical flow cytometer (Becton Dickson, San Jose, CA) measuring 10,000 events for each sample. Data analysis was performed with WinList software (Verity Software House, Topsham, ME). Cells with fluorescent beads were analyzed against cells with cold treatment, fluorescent beads, and cytochalasin D treatment. The percent phagocytosis in the experimental groups was assessed after subtracting the percent positively stained cells in the negative control treatment group.
Antibody phenotyping of macrophage cell lines and flow cytometry. ASD1, ASD2, 2ASD1.10, and 2BSD1.10 cells were phenotyped using fluorescent antibody as was previously described (Potts et al. 2008 ) using the predetermined optimal concentration of primary or isotype antibodies for an hour on ice (Table 2 ). Samples were analyzed by flow cytometry as described for phagocytosis. Percent expression in the experimental samples was determined after subtracting the background staining from its respective negative isotype control.
Assessment of cell growth. To determine cell growth, cells were dispersed, counted, and plated in a Costar 96-well, flat-bottom tissue culture plate at 1,000 cells per well in 100 µl DMEM 2 . Cells were then incubated at 37°C in 8% CO 2 . At 1, 24, 48, 72, 96, and 120 h, 100 µl of 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) were added to quadruplicate wells of each cell line. Formazin was dissolved by adding 100 μl of IsoPBS (66.649% isopropyl alcohol, 33.324% PBS, 0.027% 5 N HCl) to the wells to dissolve the crystals. Absorbance was read at 570 nm using a microtiter plate spectrophotometer (Spectra Count Plate Reader Version 3.0, Packard Bioscience and Instrument Company, Inc., Meriden, CT). Cells numbers were also enumerated directly using a hemacytometer. Cells, 5×10 4 , were seeded into wells of a 24-well plate. The following day and each test day thereafter, the medium was aspirated from triplicate wells and the cells were washed with 1 ml PBS. The cells were dispersed for enumeration on a hemacytometer. Viability was assessed with trypan blue (Sigma). , were resuspended in 500 μl of the complexed DNA medium. The cells were incubated at room temperature for 20 min with occasional pipetting to keep the cells in suspension. The cells were transferred to a well in a 6-well plate, 500 μl of serum-free Opti-MEM added and the cells were incubated overnight at 37°C. The following day, 2 ml of DMEM 2 were added and the cells were returned to the incubator. After a 2-d incubation/recovery period, hygromycin B (InvivoGen, San Diego, CA) was added directly to the medium to a final concentration of 5 mg per ml. Selection was done for 2 d and the remaining viable cells were washed free of the antibiotic and 3 ml of fresh DMEM 2 medium was added. When the remaining cells began to grow, the antibiotic was reapplied for 2 d before cloning by limiting dilution under selective conditions to establish stable tranfectants.
Real-time RT-PCR. The primers and probes for quantitative real-time RT-PCR for 14S ribosomal protein RNA, TSP2, CD81 (IDT), and EWI-2 (Sigma) are listed in Table 1 . The RNA concentration was adjusted to 100 ng per 5 μl in RNase-free H 2 O containing 1 μl RNasin per 50 μl (40 U per μl, Promega). Each RT-PCR reaction received 5 μl or 100 ng of total RNA. Each 25 μl reaction contained 9 μl RNase-free H 2 O, 5 μl 5× buffer (RT-PCR system, Promega), 3 μl 25 mM MgSO 4 , 1 μl 10 mM dNTP, 0.75 μl Taq (5 U per μl, Promega), 0.25 μl 10 μM reverse primer, 0.25 μl 10 μM forward primer, 0.25 μl 10 μM probe, and 5 μl prepared total RNA, with or without 0.5 μl AMV reverse transcriptase (Promega). Real-time RT-PCR was performed in a BioRad icycler using the following program: 45 min at 45°C followed by 40 cycles of 30 s at 95°C, 30 s at 55°C and 25 s at 72°C. The PCR efficiency was calculated from the following equation 10 −1/slope , whereby the slope was determined as a function of CT values vs. the log values of the RNA concentration. The PCR reactions were assessed to be 97% to 100% efficient over a 2 to 3 log serial dilution (Pfaffl 2001) . To assess CD81 transcriptional activity, approximately 2.5×10 5 cells were seeded per well of a 6-well plate. Starting the following day and every test day thereafter, the cells were removed, enumerated on a hemacytometer, and dissolved in Tri-reagent for RNA isolation.
Statistical analysis. All experiments were repeated as described in the legends. Data are reported as mean± standard error of the mean (SEM). Data were analyzed by paired Student's t-test. Data with P values≤0.05 were considered significantly different.
Results

Isolation of CD81
−/− and CD81 +/− macrophage cell lines.
Female CD81
−/− mice have low fecundity (Rubinstein et al. 2006 ). Therefore, it was not practical to maintain this knockout strain with homozygous breeders. This initially limited our access to homozygous CD81 −/− mice and their tissues. Our group has established and characterized other macrophage cell lines (Chapes et al. 1988; Beharka et al. 1998) . Therefore, we decided to create a bone marrowderived CD81 −/− macrophage cell line to have a consistent source of CD81 −/− cells.
Attempts to create a spontaneously immortalized macrophage cell line were unsuccessful and led to the effort described here. Bone marrow was obtained from two mice that were initially screened as CD81-negative. Bone marrow cells were pooled and placed in culture with M-CSF for 1 wk to induce macrophage differentiation and were subsequently transfected with SV40 large T antigen. After transfection, we observed continuous cell growth and RT-PCR of RNA from the cells verified that the cells were SV40 large T-antigen-positive. Cells were adherent and were passable using standard tissue culture techniques and reagents (0.25% trypsin/0.2% EDTA). Cells tested for expression of CD81 were positive, which was inconsistent with the initial genotyping of tail tissue. Subsequent genotyping of cells verified that the cells were CD81 +/− . These cells were named "Balb/c macrophage cells". Some of these cells were frozen at passage 10 and a culture was maintained in vitro for approximately 1 yr. At passage 110, we discovered that the Balb/c macrophage cells no longer expressed CD81 or carried the wild-type allele using both RNA and DNA analyses. Re-examination of a DNA sample of Balb/c macrophage cells at passage 12 and frozen cells at passage 10 verified that the cells were initially CD81 +/− . Therefore, the cells lost CD81 expression after passage 12 due to a mutation or because the original culture was a mixture of CD81 +/− and CD81 −/− cells. The Balb/c macrophage cells were made from a mixture of bone marrow from two mice. Therefore, it was possible that one of the mice was CD81 +/− and one was CD81 −/− .
To test the hypothesis that the original Balb/c macrophage cell line was a heterogeneous population and that, over time, CD81
−/− cells outgrew the CD81 +/− cells, we did two experiments. In the first experiment, we thawed Balb/c macrophage cells that had been frozen at passage 10. The cells were monitored over several passages for the presence of CD81 (Fig. 1) . We observed that at passage 13, Balb/c macrophage cell DNA was positive for CD81. However, over time, we observed a steady decrease in CD81 DNA. In fact, by passage 50, we could no longer detect CD81 by PCR (Fig. 1) . Therefore, we confirmed our first serendipitous observation that a CD81
−/− population out-competed the initial CD81 +/− cell population. In the second experiment, cells from passage 10 or 110 (Fig. 2) were subjected to limiting dilution cloning. We identified both CD81 +/− and CD81 −/− cell genotypes in passage 10 subclones (Fig. 2) . These data confirmed that the original Balb/c macrophage cells were a heterogeneous population. The ), were established (Fig. 2) . All four cell lines tested positive for SV40 large-T antigen by RT-PCR (Fig. 2) . Therefore, we successfully transformed at least two and perhaps four independent cell lines with SV40 large T antigen during the original transfection. Moreover, we have established four cell lines with two different CD81 genotypes, ASD1 (CD81 (Fig. 3) that can be maintained in standard tissue culture.
Determining the lineage of the isolated cell lines. The bone marrow cells used to create the four cell lines were originally cultured with macrophage colony-stimulating factor. This would be expected to induce these cells into the macrophage lineage (Das et al. 1981 ). Therefore, we tested the hypothesis that ASD1, ASD2, 2ASD1.10, and 2BSD1.10 cell lines were macrophages. Macrophages function in the innate immune system by eliminating bacteria through phagocytosis (Esashi et al. 2003) . Macrophages are also distinguished from other cells by the presence or absence of certain cellular surface proteins. To determine the lineage of our cell lines, we tested the cells for their cell surface phenotype and determined whether the cell lines were phagocytic. We found that all four cell lines were phagocytic (Fig. 4A) . Although there was experimentto-experiment variation, peak phagocytosis approached the phagocytosis levels of primary peritoneal macrophages (Fig. 4B) .
When we phenotyped the cells by flow cytometry, we assessed a wide variety of markers for cells in different stages of macrophage differentiation along with a few proteins that would be expressed by cells other than macrophages. 2ASD1.10 and 2BSD1.10 expressed CD81 while ASD1 and ASD2 did not (Table 3) . ASD1, ASD2, 2ASD1.10, and 2BSD1.10 expressed low levels of B220 and CD11c, which are expressed by B cells and dendritic cells, respectively (Table 3) . There were some cell line-tocell line differences in expression of some markers. For example, Ly6C was lower on the CD81 −/− clones (ASD1 and ASD2) compared to the CD81 +/− clones (2ASD1.10 and 2BSD1.10) (Table 3) . However, the CD81-negative clones expressed higher levels of Gr-1 (Ly6G) than the other cell lines. 2BSD1.10 expressed higher levels of CCR2 (MCP-1 receptor) than any of the other cell lines. ASD1 expressed lower levels of PU.1 compared to 2ASD1.10. However, all the cell lines expressed c-fms, indicating that they are in the macrophage lineage (Chan et al. 1998 ). All the cell lines expressed very low levels of the macrophage differentiation antigens F4/80, ER-MP58, CD11b, and CD31, but high levels of Mac-2. Therefore, based on a composite expression profile of mature macrophage marker Mac-2 and macrophage lineage markers c-fms and Ly-6C, we placed the cell lines in an early-to-mid macrophage differentiation stage. The CD81 +/− cell lines may be more differentiated than the CD81 −/− cell lines based on higher Ly-6C and lower Ly-6G expression.
Determination of cell division times. The CD81 −/− cell lines appeared to outgrow the CD81 +/− cell lines over time (Fig. 1) . The observation that the CD81 +/− cell lines 2ASD1.10 and 2BSD1.10 might be more differentiated, and might grow more slowly, would be consistent with that hypothesis (Metcalf 1989; DeKoter et al. 1998) . To test the hypothesis that the homozygous CD81-negative cell lines grew faster than the CD81-heterozygous cell lines, we compared their growth rates during log phase growth (24-120 h) using MTT to assess cell number. At times, 2ASD1.10 grew slower than the other three cell lines (Fig. 5B ) but its growth was irregular and often there was no statistical difference in the growth of the four cell lines (Fig. 5A ). When we compared the overall density of cells when cultures reached plateau phase/confluency at around 120 h, we found that ASD1 and ASD2 cells reached higher densities than 2ASD1.10 and 2BSD1.10 macrophage cells (Fig. 5B) . It was possible that some of the growth differences among the four macrophage cell lines were due to independent cellular transformations by SV40 T antigen and not due to CD81. Therefore, to directly compare the impact of CD81 on cell growth, we reexpressed mouse CD81 in transfected ASD1 cells. We found that ASD1 cells transfected with vector alone (open symbols; V) reached densities greater than 1×10 6 cells per 60-mm plate at confluency (Fig. 6) . In contrast, ASD1 cells transfected with CD81 (closed symbols; CD81) did not reached densities greater than 5×10 5 cells/60-mm plate (Fig. 6) . We observed that the CD81-expressing cells tended to be larger (even compared to 2ASD1.10 and 2BSD1.10) and reached confluency at a lower density than vector-transfected cells explaining the relatively flat growth curve. The over-expressing clones also formed a more contiguous, smooth monolayer compared to 2ASD1.10 and 2BSD1.10. The non-CD81-expressing cells preferred to pile on the adherent cells rather than form smooth monolayers. These growth characteristics have been observed in several different clones transformed with CD81 from at least two independent transfection experiments (Fig. 6) . Therefore, the expression of recombinant CD81 in CD81-negative cells reproducibly affects cell densities.
During the course of our experiments, we noted inconsistent CD81 transcript levels that appeared to vary with cell density. Concurrent assessment of CD81 transcript levels, measured by quantitative RT-PCR and cell growth indicated that CD81 transcript levels increased dramatically in 2ASD1.10 cells as cultures reached confluency when compared to the 14S ribosomal protein gene (Fig. 7A, B) . Interestingly, as 2ASD1.10 cells reached confluency and as CD81 transcript increased, the transcript level of EWI-2, another tetraspanin-associated protein (Clark et al. 2001; Charrin et al. 2003) was unchanged (Fig. 7A ). Similarly, the transcript level of a tetraspanin closely related to CD81, TSP2 (Huang et al. 2005) , did not consistently increase in the same cells (Fig. 7B) . Therefore, the increase in CD81 transcript levels was specific to CD81. We also examined the CD81 transcript levels in 2BSD1.10 cells when these cells reached confluency and there also was an increase in transcript levels when these cells entered stationary phase (Fig. 7C) . Although 2BSD1.10 cells generally reached stationary phase before 2ASD1.10 cells (Figs. 7C and 8) , changes in CD81 transcript levels were accompanied by increased surface expression of CD81 in both cell types as they reached confluency (Fig. 8) . Therefore, these macrophage cells appeared to upregulate CD81 as cell numbers increased.
We examined if a non-macrophage cell line, LM929 (Kuchler and Merchant 1956) , also exhibited increased CD81 expression as cell density increased. Indeed, CD81 transcript levels increased as LM929 cell density reached the plateau phase of cell growth (Fig. 9A) . Furthermore, the increased transcript levels were accompanied by an increase in surface expression of CD81 at levels higher than CD81 is expressed on 2ASD1.10 or 2BSD1.10 (Fig. 9B) . It should be noted that LM929 cells are homozygous for CD81, while the macrophage cell lines are heterozygous. These data suggest that macrophages and other cells upregulate CD81 expression as they reach confluency.
Discussion
We created four cell lines that have macrophage properties. ASD1 and ASD2 are homozygous negative for CD81 while 2ASD1.10 and 2BSD1.10 are heterozygous for CD81. It is possible that heterozygosity causes lower surface expression of CD81 on 2ASD1.10 and 2BSD1.10 compared to LM929 cells that are homozygous for CD81 (Fig. 9) . In addition, other factors such as cell type or transformation may also influence CD81 expression. Regardless, the macrophage cells 2ASD1.10 and 2BSD1.10 express significant amounts of CD81 on their surface and its expression varies during cell growth.
CD81 is ubiquitously expressed on most nucleated cells including high levels on monocytes/macrophages (Maecker et al. 2000) . This makes experiments that involve the expression of mutated, exogenous CD81 difficult to execute. ASD1 and ASD2 cells are novel mouse cell lines that overcome this problem because they do not express endogenous CD81. They were transfected to re-express wild-type CD81 without background expression of endogenous CD81 protein. Therefore, they can be useful tools in future studies to examine the function of CD81 or other proteins. ASD1 and ASD2 are not the first mammalian granulocytic lineage cell lines described that lack CD81. U937 is a human promyelocytic cell line that lacks expression of CD81 (Sundstrom and Nilsson 1976) . However, there are several sublines of U937 and expression of CD81 on some of them has been controversial (Cocquerel et al. 2003) . Since ASD1 and ASD2 originate from CD81-knockout mice, there is no question whether these cells lack expression of CD81 and they are unique among mouse cells. All four of the new cell lines described here are in the macrophage lineage based on the expression of Mac-2 antigen, the c-fms antigen (M-CSF receptor) and Ly6C, and the low expression of B220, a B-cell molecule, and CD11c, a dendritic cell marker (Leenen et al. 1994) . The high level of CD81 expression on 2ASD1.10 and 2BSD1.10 is consistent with the high level of expression on macrophages (Maecker et al. 2000 ) and is consistent with the level of expression on the C2D macrophage cell line which has also been identified as an early differentiated macrophage (Potts et al. 2008) . It is interesting that although the cells express high levels of Mac-2, the level of expression does not correlate with the low level of expression of F4/80 and CD11b, two other markers found on macrophages. F4/ 80 is found on most macrophage subpopulations (Melnicoff et al. 1989; Chan et al. 1998) . Therefore, it is surprising that the level of expression is so low. It is possible that the expression of SV40 large T antigen has affected the expression of F4/80. If this is true, all the cell lines have been affected similarly and the effect is independent of where T antigen is integrated. It is unlikely that T-antigen integration would have occurred identically in all these new macrophage cell lines in independent transformations because SV40 T-antigen integration is usually a unique event every time a cell line is "transformed" (Chapes et al. 1987) .
Our use of the oncogene SV40 large T antigen to immortalize these cells is a common method used to induce DNA replication (Das et al. 1981; Esashi et al. 2003) . However, there are some drawbacks to this approach. For example, the cells are probably tumorigenic (Ludlow 1993) . When our group created the C2D macrophage cell line, in comparisons with its SV40 large T antigentransformed "sister" cell line C2Dt, only the T-antigenexpressing C2Dt formed tumors when injected in vivo (Beharka et al. 1998 ). This will probably limit the use of ASD1 and ASD2 to in vitro assays. T antigen affects some cellular properties and may affect some of the functions of these new macrophage cells (Kool et al. 2001) . In some cases, T antigen may affect the function of CD81 (Toledo et al. 2004) . Therefore, ASD1 and ASD2 cells will be important tools among many, to learn about CD81 function.
It is possible that 2ASD1.10 and 2BSD1.10 cells are more differentiated than ASD1 and ASD2 based on the expression of Ly6C (Leenen et al. 1990) . The high level of expression of CCR2 on 2BSD1.10 along with a low level of Ly-6G would be consistent with a more differentiated phenotype (Ferret-Bernard et al. 2004) and supports this hypothesis. However, since all the cell lines were equally phagocytic it is clear that the difference does not affect all functions.
We found that the CD81 −/− macrophage cells outcompeted CD81 +/− macrophages in two independent longterm growth experiments. Both cell types have similar doubling times during log-phase growth so the outgrowth of the CD81 −/− macrophage cells appears to result from the higher density at which the cells enter plateau phase. Indeed, the re-expression of CD81 in the CD81-negative cell, ASD1, reduced the density at which the cells entered the plateau phase of cell growth. The higher expression of CD81 in 2ASD1.10 compared to 2ASD1.10 (Figs. 8 and 9 ) correlates with the relative densities these two CD81-expressing sister cells achieve (Fig. 5B ) also supports the hypothesis that CD81 influences cell density. The finding that CD81 affects the density of these macrophage cells is consistent with a role for CD81 and other tetraspanins in tumorigenesis and growth (Claas et al. 1998; Yanez-Mo et al. 1998; Testa et al. 1999) . CD81 was originally defined as "target of anti-proliferative antibody, TAPA-1" (Oren et al. 1990). When CD81 was bound by the 5A6 antibody, there was a decrease in B-cell proliferation. The co-silencing of CD9 and CD81 increased the growth of WI38 and VA13 cells in vitro (Toledo et al. 2005 ) and also exemplifies a role in growth. Astrocytes lacking CD81 are not controlled by surrounding neurons and blocking CD81 with the anti-CD81 antibody, Eat-1, prevented the ability of neurons to inhibit astrocyte proliferation (Kelic et al. 2001) . Another anti-CD81 antibody, AMP1, inhibits astrocyte growth (Geisert et al. 1996) and microglial cell proliferation (Dijkstra et al. 2001 ) and also indicates a role for CD81 in growth regulation. Microglia are brain macrophages and are responsive to many of the same types of cytokines as other tissue macrophages (Hanisch 2002; Hanisch et al. 2004) . Therefore, the growth regulatory role of CD81 on macrophages may be a universal property within the lineage. Additional experiments will be necessary to determine this. The upregulation of CD81 transcript levels and expression in our macrophage cells as they reach confluency suggests that the macrophage cells modify CD81 expression in response to their environment. This upregulation appears to be specific to CD81 since EWI-2 and TSP2 transcript levels were not affected as cell density increased. The observations that there is a fine regulation of CD81 in mouse brain during early development (Sullivan and Geisert 1998 ) and the onset of astrocytic hyperplasia in CD81 −/− Balb/c mice (Kelic et al. 2001 ) support this hypothesis. The finding that LM929 cells also increase CD81 expression as they grow in culture suggests that this potential regulatory mechanism may also be present in cells other than macrophages. The recent work showing the inverse relationship between histone deacetylase and CD81 expression affecting glioma cell growth (Gensert et al. 2007 ) supports this hypothesis. Additional studies will be required to establish if this putative mechanism is ubiquitous. These new macrophage cell lines ASD1, ASD2, 2ASD1.10, and 2BSD1.10 will be useful in examining the mechanism of how CD81 alters cell density and perhaps the identification of a physiological ligand for CD81.
